Key Takeaways
- • Steward Health, a physician-owned hospital system, filed for bankruptcy in May 2024 after Cerberus Capital Management owned it from 2010 to 2020, sparking renewed debate over private equity's role in healthcare delivery.
- • Private equity firms generate returns through acquisition of undervalued assets, operational improvements via managerial expertise and capital infusion, and subsequent exit at higher valuations—a strategy that requires voluntary transactions and market discipline to prevent value destruction.
- • Market mechanisms inherently constrain predatory private equity behavior in healthcare; excessive pricing, quality deterioration, and labor turnover reduce target company growth and marketability, directly harming the private equity firm's exit returns and profitability.
- • Private equity financing mechanisms for healthcare targets include sale-leaseback of fixed assets and direct capital infusion, ensuring the target company receives operational liquidity rather than having purchase capital diverted to previous owners.
- • Congressional and state-level policymakers are advancing measures to restrict private equity involvement in healthcare, despite the sector's historical role in channeling innovation and managerial expertise into underperforming hospital systems.
Summary
The May 2024 bankruptcy of Steward Health has reignited policy scrutiny of private equity's influence in healthcare. As a physician-owned hospital system that fell under Cerberus Capital Management's ownership from 2010 to 2020, Steward's collapse has prompted lawmakers in Congress and state legislatures to pursue regulatory constraints on private equity participation in healthcare delivery. The bankruptcy filing has become a focal point for critics who attribute operational failures directly to private equity stewardship.
Private equity's fundamental business model relies on acquiring undervalued or mismanaged assets, applying operational improvements through enhanced management and capital investment, and then divesting at substantially higher valuations. According to Ge Bai, professor of accounting and health policy at Johns Hopkins, this "buy low, sell high" approach operates under strict market discipline. While critics worry that private equity cost-cutting leads to price gouging, quality degradation, and workforce instability, Bai notes that such behaviors ultimately undermine the target company's growth trajectory and market appeal—directly reducing the private equity firm's exit value and potential returns. This market mechanism creates a natural constraint on the most egregious operational practices.
Financing structures also shape how private equity firms inject capital into struggling healthcare systems. Rather than deploying acquisition capital directly into operations, private equity typically uses sale-leaseback arrangements of fixed assets—analogous to home-equity loans—to generate operational liquidity. This ensures the target company receives working capital for operational improvements and innovation investments. Innovation itself constitutes a core private equity lever, simultaneously driving revenue growth while reducing operational costs. Healthcare sectors that fail to attract private equity capital, Bai argues, may lack sufficient growth promise to justify investment.
Private equity transactions funded solely through private capital present taxpayers with a potential benefit: the burden of capital and operational risk rests entirely with private investors rather than public systems. As regulatory proposals advance at multiple governance levels, the debate centers on whether private equity's disciplined operational approach and capital access justify expanded healthcare involvement, or whether sectoral vulnerabilities and bankruptcy outcomes warrant tighter restrictions.
Private equity's fundamental business model relies on acquiring undervalued or mismanaged assets, applying operational improvements through enhanced management and capital investment, and then divesting at substantially higher valuations. According to Ge Bai, professor of accounting and health policy at Johns Hopkins, this "buy low, sell high" approach operates under strict market discipline. While critics worry that private equity cost-cutting leads to price gouging, quality degradation, and workforce instability, Bai notes that such behaviors ultimately undermine the target company's growth trajectory and market appeal—directly reducing the private equity firm's exit value and potential returns. This market mechanism creates a natural constraint on the most egregious operational practices.
Financing structures also shape how private equity firms inject capital into struggling healthcare systems. Rather than deploying acquisition capital directly into operations, private equity typically uses sale-leaseback arrangements of fixed assets—analogous to home-equity loans—to generate operational liquidity. This ensures the target company receives working capital for operational improvements and innovation investments. Innovation itself constitutes a core private equity lever, simultaneously driving revenue growth while reducing operational costs. Healthcare sectors that fail to attract private equity capital, Bai argues, may lack sufficient growth promise to justify investment.
Private equity transactions funded solely through private capital present taxpayers with a potential benefit: the burden of capital and operational risk rests entirely with private investors rather than public systems. As regulatory proposals advance at multiple governance levels, the debate centers on whether private equity's disciplined operational approach and capital access justify expanded healthcare involvement, or whether sectoral vulnerabilities and bankruptcy outcomes warrant tighter restrictions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.